Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.20 -0.21 (-6.14%)
As of: Oct 21, 2026 · 3:59 PM EDT

Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025)

Updated

Apimeds Pharmaceuticals US's Cash from Financing Activities was $8.49 million in Q4 2025, compared with $76,500 a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025) Analysis & Trends

For FY2025, Cash from Financing Activities at Apimeds Pharmaceuticals US came in at $20.62 million.

  • In earlier years, Cash from Financing Activities was $326,500 in FY2024 (-68.4%) and $1.03 million in FY2023.
  • Quarterly Cash from Financing Activities has moved between $76,500 (Q4 2024) and $11.86 million (Q2 2025) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 8.43 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -8.78 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -5.05 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 1.76 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -2.02 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -3.89 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -1.48 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 2.34 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -3.66 Bn
10 Apimeds Pharmaceuticals US 5.44 Mn -14.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 8.49 Mn
Jun 30, 2025 11.86 Mn
Mar 31, 2025 267,200.00
Dec 31, 2024 76,500.00
Sep 30, 2024 150,000.00
API Access

Apimeds Pharmaceuticals US Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=APUS&period=max&api_key=YOUR_API_KEY